Why Tempus AI matters
Tempus reported Q2 2026 revenue of $382.5 million, up 22% year over year, and raised full-year 2026 guidance to $1.595 to $1.605 billion on July 30, 2026. It delivered its first oncology foundation model to AstraZeneca in the quarter and agreed on July 20, 2026 to buy MRD test maker Personalis. Q1 2026 revenue grew 36% to $348.1 million.
The numberRaised 2026 revenue guidance to $1.595B-$1.605B on July 30, 2026, after Q2 revenue rose 22% to $382.5M
North Carolina connection
Tempus announced a 200-job expansion into Research Triangle Park in August 2021, per the News & Observer.
On The All Things AI 100
Listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance.
Quick answers
- What does Tempus AI do?
- Runs genomic tests and licenses de-identified clinical data and AI models for oncology and other diseases. Tempus reported Q2 2026 revenue of $382.5 million, up 22% year over year, and raised full-year 2026 guidance to $1.595 to $1.605 billion on July 30, 2026.
- What AI capabilities does Tempus AI offer?
- Tempus AI offers clinical genomic testing, algorithmic diagnostics, and licenses for de-identified clinical and molecular data used in oncology and other diseases. Tempus One is an AI assistant that lets clinicians query patient context, records, and clinical evidence. The company also provides AI models and insights that support therapy selection, clinical trial matching, and life science research.
- Why is Tempus AI on The All Things AI 100?
- Tempus AI is listed under Vertical AI and science. AI built for one field: law, medicine, drug discovery, finance. Raised 2026 revenue guidance to $1.595B-$1.605B on July 30, 2026, after Q2 revenue rose 22% to $382.5M.
- Where is Tempus AI based, and who owns it?
- Tempus AI is based in Chicago, IL, was founded in 2015 and is public (NASDAQ: TEM).